<p>Intellia Therapeutics, Inc.（納斯達克代碼：NTLA）是一家領先的臨牀階段基因編輯公司，已根據納斯達克上市規則 5635(c)(4) 宣佈了誘導性授予。該公司向新員工授予了股票期權和限制性股票單位（RSU），作為其薪酬方案的一部分。這一舉措與 Intellia 的長期戰略目標和財務預測相一致，同時也體現了其吸引和留住生物技術領域頂尖人才的承諾。</p>
<p>誘導性授予包括股票期權和限制性股票單位（RSU），旨在將新員工的利益與公司股東的利益對齊。通過提供這些授予，Intellia 展示了其對員工投資的承諾，並促進創新和成功的文化。這些授予預計會對公司的流通股產生稀釋影響，但由於為這些獎勵保留的股份數量相對較小，因此稀釋影響預計不會顯著。</p>
<p>在財務預測方面，這些誘導性授予預計會對公司的流通股產生稀釋影響。然而，由於為這些獎勵保留的股份數量相對較小，因此稀釋影響預計不會顯著。此外，這些授予旨在基於績效，即只有在達到特定績效目標時，受贈者才能完全獲得股份。這種利益對齊有助於確保新員工專注於推動公司的成功，併為其長期財務預測做出貢獻。</p>
<p>總之，誘導性授予通過吸引和留住頂尖人才、促進創新文化以及將新員工的利益與公司股東的利益對齊，與 Intellia Therapeutics 的長期戰略目標和財務預測相一致。這些授予預計會產生稀釋影響，但不會顯著，並且它們旨在基於績效，進一步增強與公司目標的對齊。</p>
<p><img src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a539c8fbb538001.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a539c8fbb538001.png"/></p>

Intellia治療

<p>Intellia Therapeutics, Inc. 宣佈根據納斯達克上市規則 5635(c)(4) 向新員工授予股票期權和限制性股票單位（RSUs）的激勵計劃。此舉旨在吸引和留住人才，同時使員工的利益與股東保持一致。儘管這些授予可能會導致一定程度的股份稀釋，但預計影響將是微乎其微的。這些授予的績效基礎特性確保員工只有在達到特定目標後才能獲得股份，從而支持公司的長期戰略目標和財務預測</p>

<p>Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage gene editing company, has announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company granted stock options and restricted stock units (RSUs) to new employees as part of their compensation packages. This move aligns with Intellia's long-term strategic goals and financial projections, as well as its commitment to attracting and retaining top talent in the biotechnology sector.</p>
<div class="lb-trans"><p>Intellia Therapeutics, Inc.（納斯達克代碼：NTLA）是一家領先的臨牀階段基因編輯公司，已根據納斯達克上市規則 5635(c)(4) 宣佈了誘導性授予。該公司向新員工授予了股票期權和限制性股票單位（RSU），作為其薪酬方案的一部分。這一舉措與 Intellia 的長期戰略目標和財務預測相一致，同時也體現了其吸引和留住生物技術領域頂尖人才的承諾。</p>
</div><p>The inducement grants consist of stock options and RSUs, which are intended to align the interests of new employees with those of the company's shareholders. By offering these grants, intellia is demonstrating its commitment to investing in its employees and fostering a culture of innovation and success. The grants are expected to be dilutive to the company's outstanding shares, but the dilution is not expected to be significant, as the number of shares reserved for these awards is relatively small compared to the company's total outstanding shares.</p>
<div class="lb-trans"><p>誘導性授予包括股票期權和限制性股票單位（RSU），旨在將新員工的利益與公司股東的利益對齊。通過提供這些授予，Intellia 展示了其對員工投資的承諾，並促進創新和成功的文化。這些授予預計會對公司的流通股產生稀釋影響，但由於為這些獎勵保留的股份數量相對較小，因此稀釋影響預計不會顯著。</p>
</div><p>In terms of financial projections, these inducement grants are expected to be dilutive to the company's outstanding shares. However, the dilution is not expected to be significant, as the number of shares reserved for these awards is relatively small compared to the company's total outstanding shares. Moreover, the grants are intended to be performance-based, meaning that the recipients will only fully vest in the shares if they meet certain performance targets. This alignment of interests helps to ensure that the new employees are focused on driving the company's success and contributing to its long-term financial projections.</p>
<div class="lb-trans"><p>在財務預測方面，這些誘導性授予預計會對公司的流通股產生稀釋影響。然而，由於為這些獎勵保留的股份數量相對較小，因此稀釋影響預計不會顯著。此外，這些授予旨在基於績效，即只有在達到特定績效目標時，受贈者才能完全獲得股份。這種利益對齊有助於確保新員工專注於推動公司的成功，併為其長期財務預測做出貢獻。</p>
</div><p>In summary, the inducement grants align with Intellia Therapeutics' long-term strategic goals and financial projections by attracting and retaining top talent, fostering a culture of innovation, and aligning the interests of new employees with those of the company's shareholders. The grants are expected to be dilutive but not significantly so, and they are designed to be performance-based, further enhancing their alignment with the company's objectives.</p>
<div class="lb-trans"><p>總之，誘導性授予通過吸引和留住頂尖人才、促進創新文化以及將新員工的利益與公司股東的利益對齊，與 Intellia Therapeutics 的長期戰略目標和財務預測相一致。這些授予預計會產生稀釋影響，但不會顯著，並且它們旨在基於績效，進一步增強與公司目標的對齊。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a539c8fbb538001.png" alt="" original-src="https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a539c8fbb538001.png"/></p>

Intellia 治療通過股票期權和限制性股票單位（RSU）提升員工激勵